De Novo Donor-Specific HLA Antibody Development and Peripheral CD4⁺CD25^high Cells in Kidney Transplant Recipients: A Place for Interaction?

Table 3

Graft function according to DSA development (1st year after KT).

	All; 𝑁=53 (%)	DSA negative; 𝑁=36 (%)	DSA positive; 𝑁=17 (%)	𝑃
Graft function at 1 month
SCr (mg/dL)	1.22±0.33	1.27±0.33	1.11±0.30	0.096
eGFR (by MDRD, mL/min)	68.93±27.18	65.37±23.55	76.48±33.15	0.167
Graft function at 12 months
SCr (mg/dL)	1.23±0.40	1.20±0.32	1.29±0.53	0.481
eGFR (by MDRD, mL/min)	65.69±20.04	66.27±19.53	64.44±21.64	0.759
Deltas (12 months versus 1 month)
SCr (mg/dL)	.0002±0.39	−0.07±0.36	0.15±0.43	0.053
eGFR (by MDRD, mL/min)	−2.35±21.65	0.62±19.25	−8.66±25.51	0.759
Graft function in 2010
SCr (mg/dL)	1.95±2.56	1.54 ± 1.91	2.79±3.46	0.181
eGFR (by MDRD, mL/min)	74.41±29.92	79.45 ± 26.96	64.03±33.75	0.081
Deltas (2010 versus 1 month)
SCr (mg/dL)	0.72±2.59	0.26 ± 1.99	1.67±3.40	0.129
eGFR (by MDRD, mL/min)	8.71±27.59	13.14 ± 25.47	−0.41±30.29	0.097